Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast04
2023-505928-59-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab and pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Event-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2023-505928-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505928-59-00.